amazing...this guy doesn't seem to have a clue. adalimumab not being tested, sarilumab failing, siltuximab used in small preliminary trial in Italy with no real effect and no trials in the US. But leaves out tocilizumab, which had promising results in both France and China and is initiating trials in the US, and of course leronlimab, which has shown promising results and has two acitve trials and (apparently) others in the wings.